<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04379817</url>
  </required_header>
  <id_info>
    <org_study_id>IJBMNSSTR</org_study_id>
    <nct_id>NCT04379817</nct_id>
  </id_info>
  <brief_title>Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients</brief_title>
  <acronym>SCARLET</acronym>
  <official_title>Somatostatin Receptors Imaging in Relapsing and Refractory Multiple Myeloma Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jules Bordet Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jules Bordet Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study wil assess somatostatin receptor (SSTR) expression via the uptake of Gallium-68
      labelled DOTA-conjugated SSTR targeting peptide using PET/CT imaging in multiple myeloma
      lesions pre-identified on 18F-FDG PET/CT in order to evaluate the feasibility of molecular
      radionuclide therapy in refractory and relapsing mutiple myeloma using the Lutetium-177
      radiolabelled targeting peptide.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">September 2021</completion_date>
  <primary_completion_date type="Anticipated">September 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Somatostatin receptor expression</measure>
    <time_frame>through study completion, an average of 1,5 year</time_frame>
    <description>Biodistribution of 68Ga-DOTA cojugated SSTR targeting peptide on PET/CT images</description>
  </primary_outcome>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Multiple Myeloma</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Gallium-68 labelled DOTA-conjugated SSTR targeting peptide PET/CT</intervention_name>
    <description>Assess somatostatin receptor expression</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age above or equal to 18 years

          -  Written informed consent in accordance with institutional guidelines and obtained
             prior to any study procedures

          -  Confirmed diagnosis of multiple myeloma according to the Salmon and Durie criteria

          -  Has received at least 3 lines of treatment, exposed and refractory (or non-eligible)
             to the 5 major drugs (lenalidomid, pomalidomid, bortezomib, carfilzomib, daratumumab)

          -  Life expectancy above 3 months

          -  Active (relapsing or refractory) and measurable disease (on 18F-FDG PET/CT (performed
             within 4 weeks prior SSTR PET/CT) and biologically)

          -  Adequate renal function with GFR above or equal to 30mL/min/1.73mÂ²

          -  Bone marrow aspiration and biopsy sample available within 30 days prior study
             enrolment with positive SSTR2 IHC

        Exclusion Criteria:

          -  Pregnant or lactating patients

          -  Other active neoplastic disease

          -  Treatment by another molecule that is object of investigation within 30 days prior
             SSTR PET/CT

          -  Eastern Cooperative Oncology Group Performance Status above or equal to 3

          -  Corticoids administration at a therapeutic level (total dose of 160 mg of
             dexamethasone or equivalent) two weeks prior enrolment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Wendy Delbart</last_name>
    <phone>+3225413005</phone>
    <email>wendy.delbart@bordet.be</email>
  </overall_contact>
  <location>
    <facility>
      <name>Jules Bordet Institute</name>
      <address>
        <city>Brussels</city>
        <zip>1000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Wendy Delbart</last_name>
      <phone>+3225413005</phone>
      <email>wendy.delbart@bordet.be</email>
    </contact>
    <investigator>
      <last_name>Patrick Flamen, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Nathalie Meuleman, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Belgium</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 14, 2020</study_first_submitted>
  <study_first_submitted_qc>May 4, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2020</study_first_posted>
  <last_update_submitted>May 4, 2020</last_update_submitted>
  <last_update_submitted_qc>May 4, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

